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Abstract
The immune response against early regulatory proteins of simian- and human immunodeficiency virus (SIV, HIV) has been associated with
a milder course of infection. Here, we directly compared vaccination with Tat/Rev versus Pol/Gag. Challenge infection with SIVmac32H
(pJ5) suggested that vaccination with Tat/Rev induced cellular immune responses that enabled cynomolgus macaques to more efficiently
control SIV replication than the vaccine-induced immune responses against Pol/Gag. Vaccination with Tat/Rev resulted in reduced plasma
SIV loads compared with control (P = 0.058) or Pol/Gag-vaccinated (P = 0.089) animals, with undetectable plasma viral loads in two of
the four Tat/Rev-vaccinated animals. Therefore, the results warrant further investigation of the early regulatory proteins and their potential
for vaccination against HIV.
© 2002 Published by Elsevier Science Ltd.
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1. Introduction
Candidate lentivirus vaccines have been tested with vari-
able degrees of success but correlates of protective immunity
remain largely elusive. Most of the efforts have focussed on
the induction of both humoral and cellular responses against
structural proteins [1]. However, lentivirus infection gener-
ally results in chronic infection and progression to disease
despite the presence of these immune responses [2,3].
We have previously found that longterm asymptomatic
HIV seropositive individuals have cytotoxic T lymphocyte
(CTL) responses against all the HIV proteins tested, whereas
rapid progressors initially have comparable CTL responses
against structural proteins, but not or very limitedly against
Tat and Rev [4]. The possibility that CTL responses against
early regulatory proteins are more effective in controlling
lentivirus infection was recently also supported by studies
on SIV infection in macaques [5–7].
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Preliminary vaccination experiments in macaques with
Tat alone or Tat in combination with Rev yielded encour-
aging results showing reduced primary SIV viraemia after
challenge [5,8,9]. In other studies, however, vaccination with
structural proteins in some cases also led to reduction of
primary viraemia [10]. Comparing efficacy of the different
vaccine formulations and schedules is difficult, since differ-
ent primate models for lentivirus infection vary markedly in
their read-out parameters [11]. Therefore, we directly com-
pared the ability of vaccine-induced immunity against the
early regulatory proteins Tat and Rev with that against the
late structural proteins Pol and Gag to control SIV replica-
tion after challenge.
2. Materials and methods
2.1. Immunization and challenge of macaques
Twelve cynomolgus macaques (Macaca fascicularis)
were vaccinated four times intramuscularly in a prime-boost
regimen in which two vaccinations with recombinant
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Semliki Forest virus (rSFV; at weeks 0 and 6) were followed
by two vaccinations with recombinant modified vaccinia
virus Ankara (rMVA; at weeks 12 and 16) expressing Tat
and Rev (n = 4), Pol and Gag (n = 4) or -gal (n = 4)
[8].
EDTA-blood samples were collected every 2 weeks
for plasma and isolation of peripheral blood mononuclear
cells (PBMC). Five weeks after the last immunization all
macaques were challenged intravenously with 50 MID50
SIVmac32H (pJ5).
2.2. Biochemical analysis of vaccines
The genes of the respective SIV proteins are all expressed
under specific control of the same promotor and similar lev-
els of Rev and Gag expression have been observed in vitro
(Fig. 1). CEF cells grown in 6-well tissue culture plates were
infected at an MOI of 10 with MVA or rMVA. After 24 h in-
fected monolayers were harvested by cell lysis. Lysates cor-
responding to about 5×105 infected CEF were separated by
SDS-polyacrylamide gel electrophoresis (PAGE). Proteins
were electroblotted onto nitrocellulose membranes for 2 h in
Fig. 1. Western blot analysis of SIV Rev and Gag proteins. Proteins in lysates of CEF infected with wildtype MVA (lane 1) or rMVA expressing the
SIVmac protein Rev (lane 2) or Gag–Pol (lane 3) were resolved by SDS-PAGE, transferred to a nitrocellulose membrane, and probed with mouse
monoclonal antibodies against SIV Rev (anti-Rev) or Gag (anti-Gag) proteins. M, lanes with protein standards; molecular masses (in kDa) are indicated
by the numbers on the left.
a buffer containing 25 mM Tris, 192 mM glycine and 20%
methanol (pH 8.6). After blocking overnight in PBS–2%
BSA, blots were probed with 1000-fold dilutions of mouse
monoclonal antibodies directed against SIV Rev (MAB 6.2,
kindly provided by Kai Krohn, University of Tampere, Fin-
land) or Gag-p27 proteins (KK60, kindly provided by Karen
Kent, NIBSC, Potters Bar, UK) in PBS–2% BSA for 1 h.
After being washed with PBS–0.1% Nonidet P-40, the blot
was incubated for 1 h with alkaline phosphatase-conjugated
polyclonal goat antimouse antibody (Promega, Madison,
WI) diluted 2000-fold in PBS–2% BSA, washed again, and
developed using Western blue substrate (Promega, Madison,
WI).
2.3. Serological assays
MVA-specific plasma IgG was determined using a
FACS-measured immunofluorescence assay as described
previously with an additional pre-incubation of plasma’s
on uninfected RK-13 cells [12]. SFV-specific plasma IgG
responses were similarly determined using HeLa cells that
were used 18 h after infection with SFV.
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2.4. Elispot assay
The frequency of SIV protein-specific interferon-gamma
producing cells (IPC) was determined by Elispot for
interferon-gamma (IFN). PBMC depleted for CD4 cells
(CD4-PBMC) using CD4 Dynabeads (Dynal, Hamburg,
Germany) were cultured overnight in 96-well round-botto-
med plates (Greiner, Labor Technik, Nürtingen, Germany)
in RPMI-1640 supplemented with penicillin (100 U/ml),
streptomycin (100g/ml), l-glutamine (2 mM), 2-merca-
ptoethanol (10−5 M), 10% FBS and 1% pooled serum from
naı¨ve macaques (referred to as culture medium). After
18 h cells were counted and seeded in 96-well V-bottomed
plates (Greiner) at a concentration of 1× 105 cells per well
(pre-challenge) or 0.5× 105 cells per well (post-challenge).
Autologous herpes papio virus-transformed B cells (B-LCL)
were pulsed at a cell density of 1 × 106 cells/ml with
10g/ml of 20-mer peptides with 10 amino acids over-
lapping during 1 h at 37 ◦C in a round-bottomed 96-well
plate. Tat-derived peptides (ARP7057.1–12), Rev-derived
peptides (ARP7058.1–10) and a selected set of Gag-derived
peptides were obtained from Centralized Facility for
AIDS Reagents, NIBSC. Gag-derived peptides were se-
lected to contain previously defined CTL epitopes (p26
(ARP714.4–6) p17 (EVA775.2, 5, 11–14, 17 and 21) p15
(EVA776.1–2) (Los Alamos National Laboratory, HIV
sequence database). After the pulse, half of the culture
medium was replaced by fresh medium without peptide.
After overnight incubation at 37 ◦C cells were irradiated
(30 Gy) and added to the CD4-PBMC at a 1:2 ratio. Plates
were centrifuged briefly, incubated at 37 ◦C for 1 h and
cells were transferred to Elispot plates coated with mouse
monoclonal IFN-specific antibody (U-CyTech, Utrecht,
The Netherlands). Six hours later, cells were transfered to
a round-bottomed 96-well plate and maintained in culture
medium supplemented with recombinant IL-2 during about
10 days. Subsequently, cells were expanded using PHA and
xenogenic stimulation for future analysis of specific CTL
epitopes. Elispot plates were developed with biotinylated
rabbit polyclonal IFN-detecting antibody (U-CyTech)
followed by streptavidin alkaline phophatase conjugate
(DAKO, Glostrup, Denmark) and BCIP/NBT phosphatase
substrate (Kirkegaard & Perry Laboratories, Gaithers-
burg, USA). Developed spots were quantified by light
microscopy.
2.5. Virus detection
SIV plasma viraemia was monitored by real-time
RT-PCR. We quantified viral RNA using a Taqman assay
(forward primer, 5′-CTTGGTCCATGGGGAAAGAA-3′;
reverse primer, 5′-TCAGCCCCTGATGCACTTG-3′ and
FAM/TAMRA-labelled probe, 5′-CCCCGCAATTTCCC-
CATGGC-3′) [13]. Serial dilutions of SIVmac251 viral
lysate (SanverTECH, Heerhugowaard, The Netherlands)
were spiked into negative plasma and used to calculate
the RNA copies/ml. The cell-associated viral load was
determined with an infectious center test on c8166 cells
[14].
2.6. Statistical analysis
We used repeated measures analysis of variance
(rmANOVA), assuming a compound symmetry structure
for the residual (co)variance matrix. For testing the mean
difference in plasma load of viral RNA between groups, we
used ln-transformed data from day 3 to 109. Values below
the detection limit of the real-time quantitative RT-PCR
assay were set to 500 copies/ml.
3. Results
3.1. Antibody response against the vectors
Animals were vaccinated in a prime-boost regimen, with
two doses of rSFV followed by two doses of rMVA, for
optimal induction of cellular immunity [15]. Vaccinations
were monitored via vector-specific antibodies in the plasma.
After each administration, antibody titers increased, reach-
ing similar levels in all groups at the end of the vaccinations
(Fig. 2). The kinetics of SFV- and MVA-specific antibody
responses were largely similar in all macaques upon pri-
mary and secondary vaccination, showing that indeed all the
macaques were vaccinated and that re-vaccination boosted
the immune response against the respective vectors (Fig. 2).
SIV antigens did not seem to interfere with the induction of
the immune response, despite reported immuno-modulatory
effects for Tat [16].
3.2. Cellular immune response against SIV proteins
The number of SIV-specific IPC was quantified with an
Elispot. At the day of challenge, no SIV-specific IPC were
found in the control animals (Fig. 3). In Tat/Rev-vaccinated
animals IPC against Tat and Rev (40–6880 IPC/106
CD4-PBMC) could be demonstrated, but not against Gag.
Conversely, Gag/Pol-vaccinated animals had developed IPC
against Gag (10–2700 IPC/106 CD4-PBMC), but not
against Tat or Rev.
After challenge, when viral loads declined, control
animals had developed a cellular immune response
against SIV. This was demonstrated by moderate levels
of IPC against all three antigens tested (Fig. 3; 60–1220
IPC/106 CD4-PBMC). In Tat/Rev-vaccinated animals,
IPC against vaccine antigens were still detectable, but
only one animal had developed low numbers of IPC
against Gag. Similarly, Gag-specific responses were retai-
ned in animals vaccinated with Gag/Pol and two ani-
mals had acquired low numbers of IPC specific for Tat
and Rev.
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Fig. 2. Development of IgG plasma responses against the vaccine vectors (rSFV; left and rMVA; right) in macaques vaccinated with control vectors
(top), Tat and Rev expressing vectors (middle) and Pol and Gag expressing vectors (bottom). The four vaccinations are indicated (arrows) as well as the
moment of infection SIV infection (asterisk). The data are presented as fluorescence intensity (average± S.D.). An arbitrary cut-off level was chosen at
the average + 2× S.D. (dotted line).
3.3. SIV viral loads
After challenge with the high dose of infectious virus
all animals became infected (Table 1). One control ani-
mal became persistently viremic and three had a transient
viraemia which is common for this model of lentivirus infec-
tion [17]. Two of the Tat/Rev-vaccinated animals remained
negative for plasma viraemia (Fig. 4). The other two had
a short viraemia, with little virus production. By contrast,
Gag/Pol-vaccinated animals all developed detectable plasma
viral loads similar to the control animals and two were still
positive at the end of the observation period. The differences
between the groups were only borderline significant (Tat/Rev
versus control P = 0.058 and Tat/Rev versus Pol/Gag P =
0.089), likely due to the small number of animals tested.
The data from the infectious centre test showed similar
trends as the plasma viral loads. From all animals, virus
could be isolated at some stage after challenge (Table 1).
The Tat/Rev-vaccinated animals cleared the virus infected
cells faster and only one animal had remained virus
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Fig. 3. Numbers of Tat-, Rev- and Gag-specific IFN-producing cells (IPC) in CD4-depleted PBMC collected at the day of challenge (upper panel) or
at day 20∗ after challenge (lower panel) assessed by an Elispot assay. Spots were quantified visually by light microscopy. ∗Occasionally, when PBMC
collected at day 20 were not available, samples from day 27 or 33 were used instead (#TR6 and #TR8: Gag peptides, #PG12: Tat and Rev peptides).
The horizontal lines in the graphs indicate the mean value of the group.
Fig. 4. Detection of plasma viral loads. Plasma viraemia was measured using a real-time quantitative RT-PCR [13]. The detection cut-off was 500 SIV
RNA copies/ml.
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Table 1
Detection of cell-associated viral load
Day after SIV challenge Control Tat and Rev Pol and Gag
C1 C2 C3 C4 TR5 TR6 TR7 TR8 PG9 PG10 PG11 PG12
3 –a – 1 1 1 1 1 – 25 1 – –
6 – – 125 1 – – – – 5 – – –
10 1 25 ≥625 125 125 25 1 1 125 125 ≥625 125
13 25 125 ≥625 ≥625 ≥625 ≥625 5 25 125 ≥625 ≥625 ≥625
17 25 ≥625 ≥625 ≥625 125 5 ≥626 – ≥625 ≥625 ≥625 ≥625
20 ≥625 ≥625 125 ≥625 ≥625 125 ≥625 1 ≥625 ≥625 ≥625 ≥625
27 ≥625 ≥625 125 ≥625 ≥625 125 25 5 125 ≥625 ≥625 25
33 1 125 125 25 25 1 125 – 25 5 25 –
41 1 25 25 ≥625 25 – 5 – 25 25 25 –
48 1 25 – ≥625 25 – 5 – 125 25 ≥625 –
55 – 5 5 ≥625 – – 25 – 125 5 125 –
72 125 – 25 3125 – 1 5 – 25 1 3125 –
88 5 – 25 3125 – – 5 – 25 1 3125 1
The number of SIV-infected cells per 106 PBMC isolated from blood samples collected at different days after intravenous infection with 50 MID50
SIVmac32H (pJ5) were detected using an infectious center test [17].
a Less than one infected cell per 106 PBMC.
positive at the end of the experiment. By contrast, infected
cells were persistently detected in 3/4 and 4/4 control and
Gag/Pol-vaccinated animals, respectively.
4. Discussion
Here, we compared the effect of vaccination with early
versus late SIV proteins on the induction of specific im-
munity and containment of challenge. The SIV-vaccinated
animals, but not the control animals, had developed
SIV-specific IPC at the day of challenge. Despite pre-existing
immunity, all animals became infected, but two Tat/Rev-
vaccinated animals with high numbers of Tat-specific IPC
remained negative for plasma viraemia. There was, how-
ever, a provocative trend in that Tat/Rev-vaccinated animals
better controlled viraemia.
We and others previously found that, CTL against struc-
tural proteins are ubiquitous in lentivirus infection, but
that Tat/Rev-specific CTL correlate with a low viraemia
and a benign course of infection [4,17,18]. From these
data it could not be inferred whether the beneficial ef-
fect of Tat/Rev-specific CTL was the consequence of a
broader response in general, or whether it was intrinsic
to Tat and/or Rev-specific CTL. Our current study ar-
gues against the breadth of the immune response as an
explanation, since each vaccine contained two proteins.
Moreover, Gag and Pol are much larger proteins and may,
therefore, induce more CTL populations with different
specificities. Therefore, we favor the hypothesis that early
expression of Tat and Rev during the virus replication cy-
cle contributes to timely elimination of infected cells and
more effective reduction of the amount of virus produced
(van Baalen, submitted).
Of note, a bias in the immune response of the vaccinated
macaques was observed after challenge. Whereas control
animals developed IPC against all antigens tested, vacci-
nated animals had a preference for the antigens used in
vaccination. This may have resulted from immune-mediated
limitation of viral replication, which could hamper sensi-
tization to SIV antigens that were encountered only after
vaccination. This explanation is, however, not consistent
with the data. Two of the three animals that developed IPC
against non-vaccine antigen showed no (TR6) or limited
(PG12) plasma viraemia after challenge. In all animals with
high vireamia, an increase in IPC against SIV antigens
that were included in the vaccine was observed. On the
other hand, the immune system may have become skewed
towards the antigens as a result of the vaccination. In that
case, and if CTL against early proteins are indeed more
protective, vaccination with viral structural proteins may be
suboptimal or even counterproductive.
In this study, vaccination with Gag/Pol did not result in
any noticeable effect on virus replication, whereas in other
studies some protection has been reported [10]. It is impor-
tant to realize these vaccinations have been carried out in
different models, which may explain the discrepancy in re-
sults. Infection of cynomolgus macaques with SIVmac32H
(pJ5) results in low level, transient viraemia, which is milder
than HIV-1 in humans. Other primate models for lentivirus
infection give much higher viral loads during primary in-
fection and a more rapid progression to disease and death
than HIV-1 infection [11]. It will therefore, be useful to
perform comparative studies in these models to further eval-
uate the effectiveness of different vaccine strategies against
HIV.
Collectively, our and other observations point to an advan-
tage of specific immunity directed against the early proteins
Tat and Rev in controlling viraemia in lentivirus infections
[5,8,9]. Therefore, we emphasize that the use of early regu-
latory proteins should be given serious consideration in the
development of HIV vaccination strategies [4].
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